Business

Moderna’s Cancer Vaccine Faces Scrutiny

Updated 2026-10-23 19:05 UTC 1 source Neutral

Moderna's cancer vaccine is under scrutiny as the first Phase 3 data raises questions about its long-term effectiveness. The potential treatment aims to prevent cancer recurrence, but market expectations are high.

Coverage timeline — 1 article

MarketWatch

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.

2026-10-23 18:58 UTC